Nitto-denko Corporation

Avanir Pharmaceuticals

Avanir Pharmaceutials

Wenbin Ying

Jagadish C Sircar

Kenjirou Minomi

Sunil Kumar K C

Andrew J Baird

Robert Z Florkiewicz

Federico C A Gaeta

Jerry Anchin

Mohammad Ahmadian

Roger C Adami

Bharat Majeti

Jens Harborth

Kwok Yin Tsang

John Gaudette

Joseph E Payne

Victor Knopov

Richard P Witte

Violetta Akopian

Li Wang

Jun Zhang

Yoshiro Niitsu

Hirokazu Takahashi

Jihua Liu

Haiqing Yin

Hao Bai

Cima Cina

Elena Feinstein

Igor Mett

Hagar Kalinski

Yasunobu Tanaka

Loren A Perelman

Kenjiro Minomi

Sharon Avkin-Nahum

Yun Liu

Sunil Kumar Kc

Priya Prakash Karmali

Zheng Hou

Erika Terada

Lei Yu

Seiji Nukui

Hai Wang

Narendra Vaish

Yuwei Wang

Liping Wang

Dong Liu

Neda Safarzadeh

Roger Adami

Jane Zheng

Sridhar C Nagarajan

Akihiro Yoneda

Timothy Davis

Sunil Mumar K C

Jean-Pierre Clamme

Federico CA Gaeta

Yun Lui

Yasuaki Tamura

Sharon Avkin-nachum

John A Gaudette

Priya Karmali

Fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, compounds, compositions and methods are to provide nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

Fusogenic compounds for delivery of biologically active molecules

Ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, the compounds, compositions and methods are to provide nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

Ionizable compounds and compositions and uses thereof

Compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.

Compositions and methods for nanoparticle lyophile forms

This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2′-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.

SiRNA structures for high activity and reduced off target

This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.

This invention provides formulations for use in distributing RNAi molecules targeted to a human GST-&#x3c0; for treating a malignant tumor in a subject. The formulation can include nanoparticles composed of an ionizable lipid, a DSPE lipid, and additional lipids. A drug product can be made by lyophilization of the formulation. This invention further provides methods for ameliorating or treating a malignant tumor by administering a therapeutically effective amount of a formulation containing the RNAi agents.

RNA interference delivery formulation and methods for malignant tumors

This invention provides compounds, compositions and methods for modulating the expression of human GST-&#x3c0; using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2'-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

RNA interference agents for GST-PI gene modulation

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-&#x3c0;.

Methods and compositions for treating malignant tumors associated with KRAS mutation

This invention includes fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2'-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.

This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor, which may be associated with KRAS mutation in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-&#x3c0;.

This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-&#x3c0;, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.

RNA interference compositions and methods for malignant tumors

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

Lipids for therapeutic agent delivery formulations

RNA interference agents for GST-&#x3c0; gene modulation

Growing community of inventors

San Diego, CA, United States of America

Wenbin Ying